MariTide / maridebart cafraglutide
Phase 3Reported ongoing MARITIME-1 and MARITIME-2 phase 3 studies for weight management.
FROM PUBLIC EVENTS · 2026-11-18
Late clinical · capacity Advancing MariTide Phase 3 trials for weight management and expanding Phase 3 recruitment for cardiovascular disease, heart failure and sleep apnea Also seen: Commercial · sales
Roles often seen at this stageClinical & PV · Regulatory affairs · Medical & MSL
Official name · Amgen Inc.
Develops and markets biologic medicines across disease areas and advances obesity and metabolic candidates.
Reported ongoing MARITIME-1 and MARITIME-2 phase 3 studies for weight management.
Reported enrollment in MariTide phase 3 studies covering cardiovascular outcomes, heart failure and sleep apnea.
Individual vacancy
Observed 2026-10-03
A brief based on selected official material, not an exhaustive product or vacancy list.